Mild Cognitive Impairment Clinical Trial
— SYNERGIC@HomOfficial title:
SYNchronizing Exercises, Remedies in Gait and Cognition at Home: Feasibility of a Home-based Double-blind Randomized Controlled Trial to Improve Gait and Cognition in Individuals at Risk for Dementia
NCT number | NCT04997681 |
Other study ID # | SYNH001 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | July 28, 2021 |
Est. completion date | July 27, 2023 |
Verified date | September 2023 |
Source | University of New Brunswick |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background: Prevention of Alzheimer's Disease and Related Dementias (ADRDs) may be possible for persons with subjective (SCI) or mild cognitive impairment (MCI), or normal cognition and risk factors. Physical exercise and cognitive training have been shown to enhance cognitive function and mobility in MCI when delivered in a research facility. The feasibility of delivering interventions in the home of older adults at risk for developing ADRDs is not known. What preferences the participants have for these interventions are also unknown. The primary goals are: 1) assess feasibility of a home-based delivery of exercise and cognitive interventions 2) evaluate the relationship between participants' intervention preferences and adherence. Secondary objectives focus on cognition, frailty, mobility, sleep, diet and mental health. Methods and analysis: SYNERGIC@Home is a randomized control trial (using a 2 x 2 factorial design) with a 16-week home-based intervention program of physical exercises with cognitive training. Sixty-four participants will be randomized in blocks of four: 1) combined exercise (aerobic and resistance) + cognitive training (NEUROPEAKâ˘); 2) combined exercise + control cognitive training (web searching); 3) control exercise (balance and toning) + cognitive training; and 4) control exercise + control cognitive training. It will be implemented virtually through video conferencing. Baseline, 4- and 10-month post-intervention will include measures of cognition, frailty, mobility, sleep, diet, and psychological health. Feasibility outcomes include recruitment and retention. Preference will be used to determine the relationship between preference adherence. Secondary outcomes will evaluate the effect of the interventions on cognitive, mobility, and general well-being.
Status | Completed |
Enrollment | 60 |
Est. completion date | July 27, 2023 |
Est. primary completion date | March 8, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years to 90 Years |
Eligibility | Inclusion Criteria: - Age 60 to 90 years old. - Has a Family Physician - Has internet access (and have regular access to email), and the technology ability (able to send and receive emails). - Resides in their own home/apartment in the community. - Has access to a home computer and/or a tablet computer device. - Self-reported levels of proficiency in English and/or French for speaking and understanding spoken and written language. - Able to comply with scheduled home-based assessments, interventions, and other trial procedures. - Able to ambulate at least 10 m independently with or without a walking aid. - Being at risk of developing dementia: 1. Mild Cognitive Impairment (MCI) Group. Diagnosis of Mild Cognitive Impairment, in accordance with the criteria used in the Comprehensive Assessment of Neurodegeneration and Dementia (COMPASS-ND) study2 (Table 1). 2. Subjective Cognitive Impairment (SCI) Group. Diagnosis of Subjective Cognitive Impairment, in accordance with the COMPASS-ND study2 definition (Table 1). 3. Cognitively Intact with Risk Factors Group. Cognitively Intact based on COMPASS ND study2 definition (Table 1)) AND have a history of two or more risk factors for dementia, defined as the following (Table 1): - Obesity: Defined as a Body Mass Index (BMI) > 30 kg/m2 (as derived from the National Institute of Health BMI calculator52) - Hypertension: Defined as a documented Systolic Blood Pressure > 140 mm Hg, OR a physician's diagnosis of hypertension, OR presence of physician prescribed medical treatment for hypertension, OR other approaches to treatment for hypertension (i.e., diet or exercise). - Diabetes: Defined as a physician's diagnosis of diabetes, OR presence of physician prescribed medical treatment for diabetes, OR other approaches to treatment for diabetes (i.e., diet or exercise). - Cardiovascular disease: Defined as a physician's diagnosis of angina, myocardial infarction, coronary revascularization or other arterial revascularization, stroke, transient ischemic attack and/or peripheral vascular disease. - Physical inactivity: Defined as inactive, whereby active is defined as engaging in a minimum of 20-30 minutes of physical activity causing sweating and breathlessness, at least two times per week. - First-degree family history of dementia: Defined as a physician's diagnosis of dementia in a first-degree relative, including a parent, sibling, or child. - Dyslipidemia: Defined as a documented total cholesterol > 6.5 mmol/L, OR a physician's diagnosis of hypercholesterolemia, OR presence of physician prescribed medical treatment for hypercholesterolemia, OR other approaches to treatment (e.g. diet, exercise). - Poor sleep: Defined as a score of 6 or higher on the PSQI-18 (higher scores indicate poorer sleep). - Poor diet: Defined as a score of 7 or less on the MDA-14. - Must be medically able to participate in the study's exercise training program, as determined using the Get Active Questionnaire (a screening tool developed by the Canadian Society for Exercise Physiology53), coupled with evaluation by a certified exercise physiologist and/or the study physician for clearance to participate in combined exercise training program. - Preserved activities of daily living operationalized as a score of > 14/23 on the Lawton-Brody Instrumental Activities of Daily Living (IADL) scale3 and confirmed by clinician's interviews. Exclusion Criteria: - A diagnosis of dementia - Participants living in Nursing Homes or Adult Residential Facilities (Special Care Homes) will be excluded. - Serious underlying disease, which, in the opinion of the study physician excludes engagement in interventions or may interfere with the participant's ability to participate fully in the study. - Has had surgery within the last two months or has planned surgery in the coming 12 months that, deemed by the study physician, could interfere with the participant's vision, hearing, mobility or any other ability to participate in the study. - Has a history of intracranial surgery. - Regular Benzodiazepine use by a participant that the study physician determines to be significant enough to interfere with the participants ability to participate in the assessments and interventions in the study will be excluded. - Presence of major depression, schizophrenia, severe anxiety or drug/alcohol abuse, or other medical illness that would prohibit them from safely participating in the study or may cause harm to the participant. - Current Parkinsonism or any neurological disorder with residual motor deficits (e.g. stroke with motor deficit), active musculoskeletal disorders (e.g. severe osteoarthritis of lower limbs), or history of knee/hip replacement affecting gait performance during the baseline assessment. - Severe visual and/or auditory impairment, which, according to the vision and hearing assessment, precludes the participant from engaging in the trial. - Intention to enroll in other clinical trials during the same time period. - Active participation in an organized and planned exercise program involving aerobic exercise and/or resistance training regimen in the previous 6 months. |
Country | Name | City | State |
---|---|---|---|
Canada | The University of New Brunswick | Fredericton | New Brunswick |
Lead Sponsor | Collaborator |
---|---|
University of New Brunswick | Horizon Health Network, Réseau de Santé Vitalité Health Network, Universite de Moncton, Western University, Canada |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Intervention Adherence | Defined as the mean percent of all Intervention sessions attended of the 48 planned sessions per participant. | Post-intervention at 4 months | |
Primary | Intervention Preference | The primary analytic goal of SYNERGIC@Home is to assess the relationship between participants' adherence to the interventions and their affinity for each intervention going into the trial. All participants will be given the Intervention Preference Questionnaire (IPQ) prior to implementation of the intervention | Baseline | |
Secondary | Recruitment Rate | Defined as the total percent of enrolled participants relative to number of people screened for eligibility. | Through study completion, an average of 10 months | |
Secondary | Retention Rate | Defined as the total percent of enrolled participants who continue throughout the trial and participate in outcomes assessments as follows:
Enrollment retention: of those enrolled participants, the % who complete immediate 4-month post intervention assessment, and; Follow-up retention: of those who complete the immediate 4-month post intervention follow-up assessment, the % of participants who complete the 6-month post-intervention follow-up assessment at 10-months. |
Through study completion, an average of 10 months | |
Secondary | Assessment Tolerability | Defined as total percent of participants not voluntarily dropping out during baseline or between baseline assessment and prior to allocation to intervention group. | Baseline | |
Secondary | Trial Experience | Trial experience is defined as participants' qualitative responses to semi-structured open-ended questions aimed at providing insights on their overall trial experience within the context of the Kirkland evaluation framework. | 10 months follow-up | |
Secondary | Adverse Events | Frequency cross-tabulation of AE severity versus AE relation to trial. | Monitored from start of study until end of study | |
Secondary | Height | This measurement will be done at home and self-reported. | Baseline | |
Secondary | Data Loss | Defined as data lost due to technical failures, personnel errors or participant non-compliance | Through study completion, an average of 10 months | |
Secondary | Weight | This measurement will done at home and self-reported. | Baseline | |
Secondary | Sex | This measurement will be self-reported. | Baseline | |
Secondary | Age | This measurement will be self-reported. | Baseline | |
Secondary | Change in Hip Circumference | This measurement will be done at home and self-reported. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Neck Circumference | This measurement will be done at home and self-reported. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in waist circumference | This measurement will be done at home and self-reported. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in blood pressure | Measured with a provided blood pressure cuff. Reported systolic/diastolic. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in heart rate | Measured with a provided blood pressure cuff. Reported in beats/minute. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Medications | This measurement will be self-reported. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Chronic Diseases | This measurement will be self-reported and will be monitored throughout the trial | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in fall history | Falls will be recorded throughout the trial, in which participants will be provided with a falls calendars, on which they will record any falls that have occurred, and the research team will collect them monthly. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Health Status and Self-Perception | Participants will answer questions on their self-perception of their health status | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Constant Fatigue | Participants will answer questions on fatigue. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Falls and Balance | Participants will answer questions on falls and balance | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Vision | Participants will answer questions on their vision | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Hearing | Participants will answer questions on their hearing | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Nutrition | Participants will answer questions on their nutrition. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Sleep | Participants will answer questions on their sleep. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Mayo Fluctuation Scale | Participants will answer questions on how they feel during a day. Scores range between 0 and 4 with higher scores meaning a worse outcome. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Telephone Cognitive Screen (TCogS) | is a widely used tool that measures cognitive function in older individuals. The telephone version of the CogS has been standardized and will be administered via video conferencing. It consists of a 26-point assessment that measures orientation, registration, attention and calculation, recall, and language | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Clinical Dementia Rating Scale (CDR) | The CDR is a validated 5-point composite scale used in longitudinal Alzheimer's Disease (AD) research to characterize cognitive and global function performance applicable to AD and related dementias.61 Information is obtained through a semi-structured interview of the patient and a reliable informant or collateral source (e.g. family member). | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in remote version of the Montreal Cognitive Assessment (MoCA) | The Full MoCA via Audio-Visual Conference consists of a 30-point test assessing the following items: short term memory recall, visuospatial abilities, executive functioning, phonemic fluency, verbal abstraction, attention, concentration, working memory, language, and orientation. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Lawton-Brody Instrumental Activities of Daily Living (IADL) scale | measures participant's ability to engage in instrumental activities of daily living via questionnaire assessing activities such as preparing meals and managing personal finances | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in ADAS-Cog Immediate Word Recall | Participants are presented with 10 high imagery words and are given three trials to learn and recall them. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in ADAS-Cog Delayed Word Recall | Participants are asked to recall the 10 high imagery words presented during the immediate word recall task after a delay of approximately 5 to 10 minutes. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in ADAS-Cog Orientation | Participants are asked 8 questions pertaining to their identity, the place, and the time. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Cognitive Functional Composite 2 (CFC-2) | The CFC-2 is a collective of different test which consists of the ADAS-Cog Immediate Word Recall, ADAS-Cog Delayed Word Recall, ADAS-Cog Orientation, Clinical Dementia Rating Sum of Boxes (CDR-SB) Cognitive portion, and the Functional Activities Questionnaire. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Functional Activities Questionnaire | It measures participant's ability to engage in instrumental activities of daily living via questionnaire assessing activities such as preparing meals and managing personal finances | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Oral Trail Making Test (TMT) A | The Oral Trail Making Test (TMT) A & B is a two-part test that assesses attention speed, and mental flexibility and has been widely used in clinical settings for assessing deficits in attention and executive functioning. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Oral Trail Making Test (TMT) B | The Oral Trail Making Test (TMT) A & B is a two-part test that assesses attention speed, and mental flexibility and has been widely used in clinical settings for assessing deficits in attention and executive functioning. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in 15-item Boston Naming Test (BNT) | The Boston Naming Test (BNT) assesses visual confrontational naming and asks participants to name simple line drawings of objects. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Logical Memory I | Logical Memory I & II (Story A) from the Wechsler memory scale assesses memory and free recall. Scores range between 0 and 25 with higher scores meaning a better outcome. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Logical Memory II | Logical Memory I & II (Story A) from the Wechsler memory scale assesses memory and free recall. Scores range between 0 and 25 with higher scores meaning a better outcome. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in ADAS-Cog Word Recognition | Participants are presented with a list of 12 words and are then asked to identify the words among a list of distractor words. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in The Delis-Kaplan Executive Function System (DKEFS) phonemic fluency test | The Delis-Kaplan Executive Function System (DKEFS) phonemic fluency test measures phonemic verbal fluency. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in The Delis-Kaplan Executive Function System (DKEFS) semantic fluency test | The Delis-Kaplan Executive Function System (DKEFS) semantic fluency test measures speed and flexibility of verbal thought. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Digit Span Backward Test | The digit span test is an auditory attention task, in which participants are asked to recall a series of numbers forward and backward. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Oral version of the Digit Symbol Modalities Test | This is a timed task that gives participants 120 seconds to orally match geometric figures with specific numbers according to a defined key (specifying which symbols are assigned to which numbers) that is provided at the top of the stimulus page. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in 18-item Pittsburgh Sleep Quality Index (PSQI-18) | This is a 18-item questionnaire to help evaluate a participants sleep quality | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Work and Sleep Diary (WSD) | A self reported work and sleep diary to track activity and sleep during the assessments. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in 14-item Mediterranean Diet Assessment (MDA-14) | A 14-item questionnaire to help evaluate a participants diet. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Eating Pattern Self-Assessment | The Eating Pattern Self-Assessment is a tool used for participants to provide a self-report on their eating patterns. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Questionnaire for Vitamin D intake | A questionnaire to determine a participant's intake of Vitamin D. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Physical Activity Scale for the Elderly (PASE) | A questionnaire to assess a participants activity level. Scores range from 0 to 400+ with higher scores meaning a better outcome. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Life Space Questionnaire (LSQ) | A questionnaire to assess a participant's mobility ability. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Clinical Frailty Scale (CFS) | This assessment will be performed by the Clinical Research Coordinator/nurse using the 9 point CFS instrument. This will allow for a determination of the clinical frailty of the participants. Scores range between 1 and 9 with higher scores meaning a worse outcome. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Short Form quality of life questionnaire (SF-36) | A 36-item questionnaire that evaluates different aspects of quality of life. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | COVID-19 Questionnaire | A questionnaire that assesses a participants experience with the current COVID-19 pandemic. Scores range from 10-40 when self reported or 8-33 when reported by a study partner. | Baseline | |
Secondary | Change in Generalized Anxiety Disorder 7 (GAD 7) | A questionnaire to establish a participant's experience with anxiety | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Geriatric Depression Scale (GDS-30) | A questionnaire to establish a participant's experience with depression | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Short Test of Functional Health Literacy in Adults (STOFHLA) | Health Literacy will be assessed using the abbreviated version of the Test of Functional Health Literacy in Adults (TOFHLA).The short version, STOFHLA, consists of 2 prose passages and 4 numeracy items. | Baseline | |
Secondary | Change in Functional Assessment of Currently Employed Technology Scale (FACETS) | The FACETS is a 10-item questionnaire with possible responses falling on a Likert-type scale, and higher scores indicating more frequent use of technology domains. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in seated dual task | Participants will be asked to name as many animals as they are able to, count backwards by 1's, and count backwards by 7's while seated. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in single-task gait | Their gait velocity will be measured 3 times. Gait variability of spatial and temporal gait variables (stride time, stride length, double support time and step width) will be measured and the coefficient of variation calculated (CV = (standard deviation / mean) x 100). | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in dual-task gait | Participants will perform three walks, once each under the following dual-task conditions: walking while naming animals, counting backwards from 100 by 1's, and counting backwards from 100 by 7's. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Change in Sit to Stand Test (STST) performance | Participants will be asked to sit and stand, from a chair, repetitively for 60 seconds. | Baseline, post-intervention at 4 months, and follow-up at 10 months | |
Secondary | Biomarkers of Alzhiemer's Disease and Related Diseases | A saliva sample will be taken to get a Polygenic Hazard Score is derived from a panel of 31 single nucleotide polymorphisms. The genetic content known as DNA, or deoxyribonucleic acid, will be analyzed in order to learn about genetic information that may increase a person's risk for developing dementia. This test is part of the overall outcome measure and is not a diagnostic test. Study participants will not receive results of this test. This test is not currently a standard of normal clinical care and is still under research to determine its utility in clinical practice. | Post intervention, at 8 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04513106 -
Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial
|
N/A | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Active, not recruiting |
NCT03167840 -
Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment
|
N/A | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Not yet recruiting |
NCT05041790 -
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
|
Phase 4 | |
Recruiting |
NCT04121156 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT02774083 -
Cognitive Training Using Feuerstein Instrumental Enrichment
|
N/A | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Enrolling by invitation |
NCT06023446 -
Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
|
||
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT02663531 -
Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease
|
N/A | |
Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
Recruiting |
NCT03507192 -
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
|
N/A |